Clarity Clinical Research

East Syracuse, New York 13057

0 studies enrolling now · 9 studies all time

What they study most

Aggression, Agitation, Alzheimer Dementia, Alzheimer Disease, Dementia, Diabetes, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver Disease (NAFLD), Psychosis, Steatohepatitis, Nonalcoholic, Type 2 Diabetes

Studies at this site

• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) — Running, not enrolling
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time — Completed
• A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224 — Completed
• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients — Completed
• A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease — Paused
• Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance — Stopped early
• A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression — Stopped early
• A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease. — Completed